medigraphic.com
ISSN 1561-3046 (Electronic)

2017, Number 4

<< Back Next >>

Rev Cub Med Mil 2017; 46 (4)

Clinical epidemiological characterization of patients with COPD and lung cancer

Ramírez RE, Sánchez RD, Castañeda FJA, Benítez SE, Pérez CAE

Language: Spanish
References: 32
Page: 349-360
PDF size: 131.30 Kb.


ABSTRACT

Introduction: Lung cancer is the most frequent neoplasm and the first cause of cancer death today.
Objective: To characterize clinically and epidemiologically smokers with COPD and non-small cell lung cancer.
Method: An observational, retrospective, cross-sectional study of patients with a diagnosis of lung cancer and COPD, during the period between January 2009 and January 2015. From 112 individuals, 55 patients were selected. Sociodemographic variables, intensity of smoking and the cumulative effect of tobacco were analyzed. In addition to the summary measures, variances analysis was used to establish the linear correlation between smoking, COPD and lung cancer.
Results: Most of the patients with lung cancer and COPD belonged to the female sex (85.7%) and 75% of those with both conditions were in groups under the age of 60 years. The age of early initiation of habit, smoking time, and number of packets of cigarettes consumed per year were the variables that showed a more significant association with both entities (p = 0.01, 0.00, and 0.02 respectively).
Conclusions: the coexistence of COPD and lung cancer was more frequent in females and in children under 60 years of age. There was greater occurrence in patients with greater intensity of smoking. There was a correlation between the cumulative effect of smoking and the likelihood of developing COPD and cancer in smokers; especially those with the longest consumption time and those who smoke the greatest number of packages per year.


REFERENCES

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, ParkinDM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86.

  2. Siegel R, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67(1):7-30.

  3. Torre LA, Siegel RL,Ward EM,Jemal A. Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev. 2016 Jan- Dec[Cited 2017 Oct 10];25(1):117-26. Availalble from: http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=26667886.

  4. Hall F. Reverse translational implications of genome-wide association studies for addiction genetics. In: Preedy V. (Ed.), the Neuropathology of Drug Additions and Drug Misuse. London: Elsevier; 2016. P. 53-60.

  5. SanchezSalcedo P, Willson DO, deTorres JP, Wessfeld JC, Berto J, Campo A, et al. Improving selection criteria for lung cancer screening. The potential role of emphysema. Am J Respir Crit Care Med. 2015[Cited 2017 Oct 10];191(8):924- 31.Availalble from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447319/.

  6. Oken MM, Hochking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. Screening by chest radiograph and lung cancer mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011[Cited 2017 Oct 10];306(17):1865-73.Availalble from: https://jamanetwork.com/journals/jama/fullarticle/1104579.

  7. Van der Aalst LM, ten Haaf K, de Koning HJ. Lung cancer screening: Latest developments and unanswered questions. Lancet Respir Med. 2016;4(9):749-61.

  8. Li K, Husing A, Sookthai D, Bergmann M, Boeing H, Becker N, et al. Selecting high-risk individuals for lung cancer screening: a prospective evaluation of existing risk models and eligibility criteria in German EPIC cohort. Cancer Prev Res (Phila) 2015;8(9):777-85.Dsiponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673786/.

  9. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, Zakher B, Fu R, Slatore CG. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med 2013[Cited 2017 Oct 10];159:411-20.Availalble from: https://www.ncbi.nlm.nih.gov/books/NBK154610/.

  10. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013[Cited 2017 Oct 10];143:e78S-92S. Availalble from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749713/.

  11. Petty TL. Are COPD and lung cancer two manifestations of the same disease? Chest 2005; 128(4):1895-98.

  12. Niewoehner DE. Clinical practice: outpatient management of severe COPD. N Engl J Med. 2010;362:1407-16.

  13. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Roelan JH,et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016 Jul;66(4):271-89.

  14. Kiyohara C, Ohno Y. Sex differences in lung cancer susceptibility: a review. Gend Med. 2010 Oct;7(5):381-401.

  15. De Matteis S, Consonni D, Pesatori AC, Bergen AW, Bertazzi PA, Caporaso NE, et al. Are women who smoke at higher risk for lung cancer than men who smoke? Am J Epidemiol. 2013;177(7):601-12.Availalble from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657535/.

  16. Powell HA, Iyen-Omofoman B, Hubbard RB, Baldwin DR, Tata LJ. The association between smoking quantity and lung cancer in men and women. Chest. 2013;143:123-9.

  17. North CM, Christiani DC. Women and Lung Cancer: What's New? Semin Thorac Cardiovasc Surg. 2014;25(2):1-13.

  18. Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Can. 2015;90:121-7.

  19. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM. Lung cancer and chronic obstructive pulmonary disease: Needs and opportunities for integrated research. J Natl Cancer Inst 2009;101:554-9.

  20. Sekine Y, Katsura H, Koh E, Hiroshima K, Fujisawa T. Early detection of COPD is important for lung cancer surveillance. Eur Respir J 2012 May;39(5):1230-40.

  21. Chen LS, Hung RJ, Baker T. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis-a meta-analysis. J. Natl. Cancer Inst. 2015[Cited 2017 Oct 10];107(5):88-93.Availalble from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822525/.

  22. Bergen AW, Javitz HS, Krasnow R. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet. Genomics. 2013;23(2):94-103.

  23. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedanallu CS,et al.Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016[Cited 2017 Oct 10];48(6):607- 16.Availalble from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884143/.

  24. Adcock I, Caramori G, Barnes P. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respir 2011;81(4):19.

  25. Young RP, Hopkins RJ. Link between COPD and lung cancer, Respir. Med 2010[Cited 2017 Oct 10]; 104(5):758-9.Availalble from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718929/.

  26. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2015;378(9795):1015-26.

  27. Papadopuolos A, Guida F, Leffondré K, Cénée F, Cyr D, Schmaus A, et al. Heavy smoking and lung cancer: Are women at higher risk? Result of the ICARE study. Br J Cancer. 2014 Mar 4;110(5):1385-91.

  28. Sprouffske K, Pepper J W, Maley CC. Accurate reconstruction of the temporal order of mutations in neoplastic progression. Cancer Prev Res (Phila). 2011 Jul;4(7):1135-44.

  29. Jia P, Pao W, Zhao Z. Patterns and processes of somatic mutations in nine major cancers. BMC Med Genomics, 2014 Feb 19;7:11.

  30. Liggett LA, De Gregori J. Changing mutational and adaptive landscapes and the genesis of cancer. Biochim Biophys Acta. 2017 Apr 1867(2):84-94.

  31. Rozhot A, De Gregori J. The evolution of lifespan and age-dependent cancer risk. Trends in cancer, 2016 Oct[Cited 2017 Oct 10];2(10):552-60.Availalble from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400291/.

  32. De Gregori J. Challenging the axiom: Does the occurrence of oncogenic mutations truly limit cancer development with age. Oncogene, July 2012;1-7.




2020     |     www.medigraphic.com